comparemela.com

Latest Breaking News On - ஜார்ஜ் டேமேற்றி - Page 1 : comparemela.com

Dana-Farber Cancer Institute Establishes David Liposarcoma Research Initiative

Date Time Dana-Farber Cancer Institute Establishes David Liposarcoma Research Initiative Dana-Farber Cancer Institute announced that The Rossy Foundation has committed $10 million to establish the David Liposarcoma Research Initiative. The five-year initiative will spearhead groundbreaking research into liposarcoma at Dana-Farber and external collaborating partner institutions, with the aim of transforming the treatment of this rare, underfunded, and understudied disease in order to improve care of patients through research. This commitment from The Rossy Foundation will focus on collaborative research among various departments at Dana-Farber-including liposarcoma biology, biochemistry, immunology, metabolism, genomics, and epigenetics. By conducting research to improve fundamental understanding of the molecular mechanisms of this disease, the initiative may lead to new approaches to overcome treatment resistance, as well as new strategies for clinical research to improve the outc

Kojin Therapeutics Debuts to Solve Difficult Diseases Through Cell Behavior

Published: Jun 09, 2021 By Mark Terry Kojin Therapeutics launched with a $60 million Series A to initially focus on oncology and cell state biology. The round was led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital. Participants included Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices. The approach came out of the laboratoryof Stuart Schreiber, Harvard University professor and co-founder of the Broad Institute. Co-founders of Kojin include Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan. The company’s technology is ferroptosis-based drug discovery, which is to say, iron-dependent cell death. Kojin says that difficult-to-treat diseases, which includes drug-resistant cancers, involve diseased cells that are sensitive to ferroptosis.

Game-changer cancer drug celebrates 20 years Gleevec turned a death sentence into a chronic disease for many

Game-changer cancer drug celebrates 20 years. Gleevec turned a death sentence into a chronic disease for many. Karen Weintraub, USA TODAY © Courtesy Mel Mann Mel Mann holds up the May 28, 2001 Time magazine, which focused on the cancer drug Gleevec, which saved his life. In the mid-1990s Mel Mann was counting down his days. His doctor had given him three years to live, and time was running out. Mann s chronic myeloid leukemia diagnosis had prompted him to retire from the Army and move to Atlanta, where he split his time between his young daughter and running bone marrow drives. His best chance for longer survival was a bone marrow transplant, but as a Black man without a matched sibling, his chances of finding a donor were slim. The previous year, only 20 African Americans had been able to find matches out of 2,000 who needed them, he remembered.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.